MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.

• Autoři: SCHAEYBROECK Van; ROLFO S; ELEZ CD; KELLY E; HOULDEN S; COLLINS J; LOVE L; ANDRE S; LAWLER T; NICOLANTONIO M Di; GRAYSON F; POPOVICI Vlad; BARDELLI VC; LAURENT-PUIG A; SALTO-TELLEZ P; MAUGHAN M; TABERNERO T; PEETERS J; WILSON M; MIDDLETON RH; MR
• Rok publikování: 2015
• Druh: Článek v odborném periodiku
• Časopis / Zdroj: Journal of clinical oncology
• www: http://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps3632
• Doi: http://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps3632